Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Actavis Must Withdraw Opana ER Generic Four Years After Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

Court finds Actavis infringed two Endo patents, judge to decide whether to award damages. Actavis' non-crush-resistant generic has impeded sales of Endo's newer crush-resistant version.


Related Content

FDA Rejects Endo’s Deadline On Opana ER Petition; Impax Product May Become New RLD
Endo Seeks To Block Generics Of Opana ER That Are Not Crush-Resistant


Related Companies